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Summary
Background—Cryptococcus is the most common cause of meningitis in adults living with HIV 
in sub-Saharan Africa. Global burden estimates are crucial to guide prevention strategies and to 
determine treatment needs, and we aimed to provide an updated estimate of global incidence of 
HIV-associated cryptococcal disease.
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Methods—We used 2014 Joint UN Programme on HIV and AIDS estimates of adults (aged >15 
years) with HIV and antiretroviral therapy (ART) coverage. Estimates of CD4 less than 100 cells 
per µL, virological failure incidence, and loss to follow-up were from published multinational 
cohorts in low-income and middle-income countries. We calculated those at risk for cryptococcal 
infection, specifically those with CD4 less than 100 cells/µL not on ART, and those with CD4 less 
than 100 cells per µL on ART but lost to follow-up or with virological failure. Cryptococcal 
antigenaemia prevalence by country was derived from 46 studies globally. Based on cryptococcal 
antigenaemia prevalence in each country and region, we estimated the annual numbers of people 
who are developing and dying from cryptococcal meningitis.
Findings—We estimated an average global cryptococcal antigenaemia prevalence of 6·0% (95% 
CI 5·8–6·2) among people with a CD4 cell count of less than 100 cells per µL, with 278 000 (95% 
CI 195 500–340 600) people positive for cryptococcal antigen globally and 223 100 (95% CI 150 
600–282 400) incident cases of cryptococcal meningitis globally in 2014. Sub-Saharan Africa 
accounted for 73% of the estimated cryptococcal meningitis cases in 2014 (162 500 cases [95% CI 
113 600–193 900]). Annual global deaths from cryptococcal meningitis were estimated at 181 100 
(95% CI 119 400–234 300), with 135 900 (75%; [95% CI 93 900–163 900]) deaths in sub-Saharan 
Africa. Globally, cryptococcal meningitis was responsible for 15% of AIDS-related deaths (95% 
CI 10–19).
Interpretation—Our analysis highlights the substantial ongoing burden of HIV-associated 
cryptococcal disease, primarily in sub-Saharan Africa. Cryptococcal meningitis is a metric of HIV 
treatment programme failure; timely HIV testing and rapid linkage to care remain an urgent 
priority.
Funding—None.
Introduction
Cryptococcus is the most common cause of meningitis in adults living with HIV in sub-
Saharan Africa.1–3 Despite antiretroviral therapy (ART) expansion, prevalence of 
cryptococcal infection is largely unchanged in low-income and middle-income countries 
(LMICs), unlike in high-income countries (HICs).4–7 Estimates of national, regional, and 
global burden of cryptococcal meningitis are crucial to guide prevention strategies and 
identify needs for diagnostic tests, antifungal medicines, and medical supplies, such as 
lumbar puncture needles and manometers.
In 2008, the global annual incidence of cryptococcosis was estimated as 957 900 cases per 
year (range 371 700–1 544 000 cases).8 This estimate was based on published cohorts from 
the pre-ART era, and the wide range indicates the high level of uncertainty of these 
estimates. Since then, extensive ART expansion has occurred; AIDS-related deaths have 
reduced by 45% from 2·0 million to 1·1 million deaths.9 The importance of asymptomatic 
cryptococcal antigenaemia as a precursor to symptomatic meningitis and death has been 
further defined,10–13 and more cryptococcal antigenaemia prevalence data have been 
published.
WHO, US President’s Emergency Plan for AIDS Relief, and US Department of Health and 
Human Services have recommended cryptococcal antigenaemia screening for people with a 
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CD4-positive T-cell count of less than 100 cells per µL who are not receiving effective ART.
14–16
 Cryptococcal antigenaemia screening coupled with pre-emptive antifungal therapy has 
a proven survival benefit,10,12,17 and has been incorporated into HIV national guidelines in 
Botswana, Kenya, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda, USA, 
and Zimbabwe with consideration elsewhere. Estimation of the cryptococcal disease burden 
helps stakeholders weigh the costs and resources required for hospital-based meningitis 
treatment versus investment of resources into a pre-emptive cryptococcal antigenaemia 
screen-and-treat strategy.18 We aimed to provide an updated estimate of the global incidence 
of HIV-associated cryptococcal disease using published UNAIDS data for HIV incidence, 
ART access, retention in care, and published cryptococcal antigen prevalence data.
Methods
Global estimates of HIV infection
We used UNAIDS 2014 country-level estimates of global incidence and cases of HIV 
infection (table 1); specifically published estimates of adults (aged >15 years) living with 
HIV, adults receiving ART, percentage of adults receiving ART among those eligible per 
WHO 2010 guidelines (CD4 <350 cells per µL) via UNAIDS 2014 spectrum estimates,24 
UNAIDS GAP report,9 and WHO Global Health Observatory database.46 Each UNAIDS 
and WHO estimate was originally published with a low and high estimate range as a 
measure of uncertainty. Using the estimates of those with a CD4 cell count of less than 350 
cells per µL on ART, and those eligible for ART, we calculated the ART gap (people who 
were not receiving ART but CD4 cell counts of <350 cells per µL). We used UNAIDS and 
WHO reports for estimates of the number of people with CD4 cell counts of less than 100 
cells per µL,19 CD4 cell counts of 100–200 cells per µL, virological failure,26 and loss to 
follow-up (table 1, appendix pp 2–6).26
For each point estimate, a 95% CI was obtained. To further account for bias and limitations 
of the primary literature, the 95% CI was widened by adding or subtracting 1·5 times the 
difference between the right and left limits, respectively. Thus, the uncertainty ranges 
described in the Methods and in table 1 are conservatively wider than 95% CI from the 
published literature.
Estimate of people at risk for cryptococcal disease
We defined the total number of people at risk for cryptococcosis by country and region as: 
adults with a CD4 cell count of less than 100 cells per µL not on ART and adults with a CD4 
cell count of less than 100 cells per µL on ART but either lost to follow-up or with 
virological failure. Those who start ART but do not have virological failure, and are negative 
for cryptococcal antigenaemia, have no risk of developing cryptococcal infection. The 
estimate of adults with a CD4 count of 100 cells per µL or less was 22·5% (range 19–26) 
among those with a CD4 cell count of less than 350 cells per µL in LMICs.19,20 In HICs, 
18·5% (range 16–21) of those with a CD4 cell count of less than 350 cells per µL were 
estimated to have a CD4 cell count of less than 100 cells per µL.19,20 Thus, we estimated the 
number of patients with a CD4 count of less than 100 cells per µL on ART from the ART 
percentage coverage (ART percentage coverage × ART eligible [CD4 <350 cells per µL] × 
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proportion with CD4 <100 cells per µL, accounting for uncertainty around those estimates; 
appendix pp 2, 3).
Based on a UNAIDS systematic review,26 we assumed 16% (range 12–20) of people 
initiating ART retained in care had virological failure at 12 months. After completion of 1 
year on ART, we assumed the virological failure incidence to be a third of that in the first 
year at 5·3% (95% CI 4·0–6·6).26–29 This Article cites observational data from Canada, the 
USA, and the UK with similar frequencies of viral suppression at 12 months.47–49 Retention 
in care is based on country level estimates from UNAIDS,24 and where data were missing, 
we used continental mean estimates.
Cryptococcal antigenaemia prevalence
We estimated the total number of people with cryptococcal antigenaemia using blood 
cryptococcal antigenaemia prevalence studies from 1989 to 2016, either in the published 
literature, or abstracts presented at conferences, among outpatient populations for 17 African 
countries, five Asian countries, five Latin American countries, the USA, and the UK (figure 
1). Cryptococcal antigenaemia prevalence studies of solely inpatient populations were 
excluded because prevalence is higher in those presenting to the hospital and not 
representative of the asymptomatic outpatient population that is ideal for cryptococcal 
antigenaemia screening. For countries with available data, cryptococcal antigenaemia 
prevalence among people with a CD4 cell count of less than 100 cells per µL was used for 
that specific country along with the associated 95% CI by Fisher’s exact test (appendix pp 4, 
10). For countries without cryptococcal antigenaemia prevalence data, we used the pooled, 
weighted continental mean estimate. Thereafter, we estimated the number of people with 
prevalent cryptococcal antigenaemia by country and region by multiplying people at risk for 
cryptococcal disease by the cryptococcal antigenaemia prevalence of the country and region 
(described earlier and in table 1).
People positive for cryptococcal antigenaemia who develop cryptococcal meningitis
Not all patients positive for cryptococcal antigenaemia develop cryptococcal meningitis. 
Estimates of adults who are positive for cryptococcal antigenaemia who go on to develop 
symptomatic cryptococcal meningitis were from published cohort studies.10–12,30–32 We 
estimated that 70% (range 56–84%) of people positive for cryptococcal antigenaemia would 
progress to develop cryptococcal disease or died without diagnosis, unless treated with ART 
or pre-emptive fluconazole (appendix p 6). Without ART or pre-emptive fluconazole 
therapy, we assumed 95% (uncertainty interval 90–100) progression in all regions (opinion 
of authors) with a 5% competing risk of death from other causes or comorbid conditions.
10,11,45,50,51
People negative for cryptococcal antigenaemia who are at risk for cryptococcal infection
The cryptococcal meningitis incidence in people with a CD4 cell count of less than 200 cells 
per µL who were initially negative for cryptococcal antigenaemia in blood before initiating 
ART is 5·14 per 100 person-years.30 This value is estimated from the only publication 
available for estimating incidence of cryptococcal meningitis before initiation of ART in 
Uganda, and for this estimation, we assumed an incidence range of 2·6–9·0 cryptococcal 
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events per 100 person-years. In high-income countries, we assumed the risk of development 
of cryptococcal meningitis was 50% lower due to more intensive virological monitoring and 
additional second-line ART options. For people with CD4 less than 200 cells per µL, 
initially prevalent cryptococcal antigenaemia-negative status and not receiving ART, we 
assumed a competing risk of starting ART or death of 50% (ie, 500 of 1000 person-years).
Annual incidence of cryptococcal meningitis
Annual incidence of cryptococcal meningitis includes the estimation of those people positive 
for cryptococcal antigenaemia who developed symptomatic meningitis, both in care and 
newly initiating ART with unmasking disease and those not in care or not on ART with 
AIDS progression.
Cryptococcal meningitis deaths
We estimated 1 year mortality in low-income countries (LICs) as 70% (uncertainty interval 
59–81) after cryptococcal meningitis for those in care and 100% for those not in care 
(appendix p 5).31,49,52–56 For middle-income countries, we presumed 1 year mortality of 
40% (uncertainty interval 34–46), based on summary statistics of outcomes of those 
receiving amphotericin B and fluconazole, and 60% for those not originally in care (ie, not 
receiving ART).40,41 In Europe (including eastern Europe and Russia), we estimated 1 year 
mortality to be 30% for those in care and 45% for those not in care (opinion of authors). In 
North America, we estimated 1 year mortality to be 20% for those in care and 30% for those 
not in care.43
Uncertainty analysis
To account for parameter uncertainty in the primary data, we used probability distributions 
to describe a range for each point estimate of interest. We varied each value in our model 
simultaneously, sampled from a priori defined probability distributions. The outputs from 
this uncertainty analysis generated CIs for each parameter. Full details of each parameter 
and distribution are available in the appendix (p 6).
We used empirical data, when available, to define distributions (appendix p 6). We used 
standard β distributions for binomial data, and normal distribution for continuous estimates. 
Using Microsoft Excel 2013, we randomly selected a value for each parameter within the 
appropriate distribution, and used the combination of these values to estimate the number of 
people positive for cryptococcal antigenaemia, annual incidence of cryptococcal meningitis, 
and number of deaths from cryptococcal meningitis for each region. Using 50 000 iterations, 
we obtained empirical distributions corresponding to posterior distributions calculated by 
Monte Carlo simulations. These distributions were used to generate a point estimate 
(posterior mean) and Monte Carlo CIs from the lower 2·5% and higher 97·5% for the 
estimates of cryptococcal antigenaemia, meningitis, and fatality from cryptococcal disease. 
Given the limited high-quality source data, we broadened our estimates of uncertainty of the 
primary data by widening our CIs to use 99·7% CI with three standard deviations above and 
below the weighted averages of included studies.
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Role of the funding source
There was no funding source for this study. The corresponding author had full access to all 
the data in the study and had final responsibility for the decision to submit for publication.
Results
In December, 2013, 31·8 million (range 30·1–33·7) adults were living with HIV globally, 
with 21·7 million (20·7–23·0) living in sub-Saharan Africa. Globally, 19·5 million adults 
were eligible for ART (CD4 <350 cells per µL) according to WHO 2010 guidelines, with 
11·3 million actually receiving ART. Globally, 8·2 million people had a CD4 count of less 
than 350 cells per µL but not receiving ART, with 5·2 million of these individuals in sub-
Saharan Africa. We estimated 4·3 million adults have a CD4 count of less than 100 cells per 
µL globally, and of these, 1·8 million (42%) were not on ART. This group is at particularly 
high risk for opportunistic infections, including cryptococcosis. In 2013, there were an 
estimated 1·4 million (range 1·1–1·6) AIDS-related deaths globally, per UNAIDS estimates.
We estimated an average global cryptococcal antigenaemia prevalence of 6·0% (95% CI 
5·8–6·2) in people with a CD4 count of less than 100 cells per µL, corresponding to 278 000 
(95% CI 195 500–340 600) people globally in 2014 (figure 2). Annually, we estimated that 
there are 223 100 (95% CI 150 600–282 400) cases of cryptococcal meningitis globally, 
with 73% of cases (162 500 [95% CI 113 600–193 900]) occurring in sub-Saharan Africa 
(table 2; appendix p 9). The region with the second highest incidence was Asia and Pacific 
(19% of total), with an annual incidence of 43 200 (95% CI 25 300–64 700) cases of 
cryptococcal meningitis (table 2). Annual fatalities from cryptococcal meningitis are 
estimated at 181 100 (95% CI 119 400–234 300) deaths globally, with 135 900 (75%; 95% 
CI 93 900–163 900) deaths occurring in sub-Saharan Africa (table 2). Table 3 highlights 
countries with the highest annual incidence of cryptococcal meningitis. Globally, 
cryptococcal meningitis results in 15% of AIDS-related mortality (95% CI 10–19). The 
appendix provides country-level listing of data for all parameters considered in the model.
Discussion
We estimated the global incidence of cryptococcal meningitis to be substantial at 223 100 
cases annually (95% CI 150 600–282 400), resulting in 181 100 (95% CI 119 400–234 300) 
annual deaths in 2014. Sub-Saharan Africa continues to have the greatest burden of this 
disease. We estimated cryptococcal meningitis causes 15% (95% CI 10–19) of AIDS-related 
deaths globally. Although the absolute number of cryptococcal deaths has decreased since 
the previous 2008 estimate,8 the proportion of AIDS-related mortality remains similar. Our 
estimates, and others, imply that cryptococcosis remains the second most common cause of 
AIDS-related mortality, only narrowly behind tuberculosis.58–63 These updated accurate 
disease estimates enable appropriate ordering of essential antifungals, diagnostics, and 
medical supplies.
Importantly, prevention of cryptococcal disease has shown survival benefit and is cost-
saving to health-care systems when coupled with enhanced ART adherence.18,41,52,64 The 
cost of cryptococcal antigenaemia screening programmes needs to be appreciated in the 
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context of the treatment costs for patients with cryptococcal meningitis in LMICs. For 
example, the per patient cost of cryptococcal meningitis treatment in Uganda with 
amphotericin B and fluconazole is US$400 for 2 weeks.41 Consolidation and maintenance 
therapy with fluconazole for 1 year costs $60 per meningitis survivor ($0·15 per 200 mg 
fluconazole) in LMICs.53 Thus, with an annual estimated incidence of 12 200 meningitis 
cases in Uganda, $5·6 million would be required for initial meningitis diagnosis and 
treatment. Conversely, if cryptococcal antigenaemia screening costs $4·0054 plus $24·60 for 
the WHO-recommended pre-emptive treatment regimen,9 screening the 110 500 people at 
risk for cryptococcal disease in Uganda with a CD4 count of less than 100 cells per µL and 
pre-emptively treating the 15 500 people positive for cryptococcal antigenaemia would cost 
$822 600, which is 15% of the cost of meningitis treatment with more than 40% better long-
term survival.33
Compared with previous 2008 estimates,8 our 2014 estimates are lower, because the HIV 
and AIDS landscape has changed with rapid ART expansion and a 45% decrease in AIDS-
related mortality from 2005 to 2013 in sub-Saharan Africa.9 We also used a different method 
of cryptococcal antigenaemia prevalence, as cryptococcal antigenaemia positive status is a 
known predictor of progression to cryptococcal meningitis. Country-specific cryptococcal 
antigenaemia prevalence data were less available previously.
Additionally, we compared our estimates with the few published estimates of the national 
incidence of HIV-associated cryptococcal meningitis. Our model estimated that there are 
2945 US cases of cryptococcal meningitis annually. In the USA, an estimated 3400 
recognised cryptococcal meningitis admissions to hospital were identified by the 
International Classification of Diseases (9th edition) hospital billing codes, of which two-
thirds were HIV-related.43 In South Africa during 2015, the national reporting laboratory-
confirmed 6174 cryptococcal meningitis cases and an additional 4295 people were positive 
for cryptococcal antigenaemia without documented meningitis.5 We estimated that there 
were 21 400 cryptococcal cases in South Africa for 2014. This discrepancy probably reflects 
a proportion of people living with AIDS not in care, undiagnosed, and lost to follow-up who 
do not receive a reported laboratory-confirmed diagnosis. An estimated 554 990 South 
Africans are living with AIDS,5 and the median CD4 count in ART-naive people entering 
care was 150 cells per µL in 2015.55 We estimated 382 400 South Africans with a CD4 
count of less than 100 cells per µL would be at risk for cryptococcal disease. In 2015, the 
South African National Health Laboratory Service processed 360 000 specimens with CD4 
counts of less than 100 cells per µL (about 10% of nationwide total) of which around 80% 
are estimated to be from unique individuals.55
One limitation of this estimate is our use of UNAIDS 2014 data,24 when 2016 data are 
available.65 The most recent figures were not used because the 2014 UNAIDS estimates 
have published numbers of people with a CD4 count of less than 350 cells per µL by 
country. We used these numbers to estimate a CD4 count of less than 100 cells per µL and 
thereby estimated the population at risk for cryptococcal infection. UNAIDS no longer 
publishes the number of people with CD4 counts of less than 350 cells per µL by country; 
thus, a 2016 estimate would require us to project this number with a CD4 count of less than 
100 cells per µL based on the proportion of people who are HIV infected, thereby adding 
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more uncertainty to our estimates. At the time of this publication, 2016 data were also 
missing in several important country estimates such as Nigeria and Ethiopia.
Further limitations of our analysis are related to the absence of UNAIDS country data for 
HICs. A second limitation is that many countries do not have any cryptococcal antigenaemia 
prevalence data available so estimates were extrapolated from countries in the region with 
cryptococcal antigenaemia data available. There is also substantial heterogeneity in studies 
reporting cryptococcal antigenaemia prevalence. Solely inpatient cryptococcal antigenaemia 
prevalence studies were excluded; however, some studies included symptomatic and 
asymptomatic people, which might overestimate point estimates for cryptococcal 
antigenaemia prevalence and yet underestimate the progression to symptomatic meningitis, 
if already symptomatic. Cryptococcal antigenaemia prevalence studies used different testing 
methods (latex agglutination vs lateral flow assay) with lower sensitivities for detection with 
latex agglutination. There are relatively few studies that have assessed progression of 
asymptomatic cryptococcal antigenaemia to symptomatic meningitis or death.10–12,31,32 Our 
estimate of asymptomatic cryptococcal antigenaemia progression to symptomatic meningitis 
was based on a weighted average of mixed studies in which most people were not treated 
with antifungals at all.11 Thus, progression to meningitis or death might be an underestimate 
and will vary with access to timely ART. To account for bias and limitations of the primary 
data, we did a probabilistic sensitivity analysis that generated Monte Carlo CIs according to 
the probability distribution of possible outcomes. Furthermore, our estimates of meningitis 
incidence and death are based on point-prevalence data over the past 10 years. These 
estimates do not reflect averages of historical trends nor are they based on dynamic disease 
models to predict future disease incidence. However, cryptococcal antigenaemia prevalence 
data have been relatively constant by country over time.10,13,56 Notably, AIDS-related 
mortality due to cryptococcosis has remained stable from previous estimates.8 However, 
with improvements in ART access and retention in care, estimates of incidence of 
cryptococcal meningitis should correspondingly decrease over time.
Despite global improvement in access to ART, the number of HIV-infected people with a 
CD4 count of less than 100 cells per µL is still substantial at about 20–25% of those 
presenting to care.66 Thus, the annual number with cryptococcal infection is high at 278 000 
globally. Cryptococcal meningitis is an excellent metric of HIV treatment programme 
failure. In 2016, no person with HIV should develop cryptococcal disease, yet due to 
challenges with late diagnosis, linkage to care, ART access, retention in care, and virological 
failure on ART,20,66,67 the often final event in a failed cascade of HIV care is the 
development of cryptococcal meningitis. Until linkage to comprehensive HIV care can be 
improved, cryptococcal screening programmes are a worthy investment that identify 
populations at high risk for death. To reduce AIDS-related deaths, it is crucial to ensure that 
people with CD4 counts of less than 100 cells per µL are screened for cryptococcal 
antigenaemia, pre-emptively treated (if cryptococcal antigenaemia positive), and initiated on 
ART. In the absence of initial CD4 testing, all people should be cryptococcal antigen 
screened.
Our analysis highlights the ongoing substantial burden of HIV-associated cryptococcal 
disease, primarily in sub- Saharan Africa but also in Asia and the Pacific. Timely HIV 
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testing and rapid linkage to care is an urgent priority. Cryptococcal antigenaemia screening 
and pre-emptive fluconazole treatment should be part of a routine package of enhanced care 
for people presenting late with AIDS at time of entering into HIV care.
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Research in context
Evidence before this study
Cryptococcus is the most common cause of meningitis in adults in sub-Saharan Africa 
due to the burden of HIV infection. We searched PubMed with the terms “cryptococcal 
meningitis” and “burden” on Feb 8, 2017, with no restrictions on language or date. The 
only study to estimate the global burden of cryptococcal infection was published in 2008. 
The global annual incidence of cryptococcosis was estimated as 957 900 cases per year 
(range 371 700–1 544 000). This estimate was based on published cohorts primarily from 
the pre-antiretroviral therapy (ART) era, and the wide ranges indicate the high level of 
uncertainty of these estimates. This 2008 study used only three incidence publications to 
derive sub-Saharan African estimates.
Since then, extensive ART expansion has occurred; AIDS-related deaths have reduced by 
39%. The importance of asymptomatic cryptococcal antigenaemia as a precursor to 
symptomatic meningitis and death has been further defined, and more cryptococcal 
antigenaemia prevalence data have been published.
Since the initial estimate of global burden of cryptococcal meningitis in 2008, small, 
retrospective studies describing the national burden of cryptococcal meningitis have been 
published in South Africa, Brazil, Ecuador, Nigeria, Tanzania, Kenya, Vietnam, Thailand, 
and USA. These studies used epidemiological, country-wide data from the local 
government, WHO, international and local reports, along with unreported data.
Added value of this study
This updated global estimate of cryptococcal infection is the first in 8 years. The 
landscape of HIV infection has changed greatly since the initial estimate of global 
burden. We provide an updated estimate of the global incidence of HIV-associated 
cryptococcal disease with published UNAIDS data for HIV incidence, ART access, 
retention in the care cascade and published cryptococcal antigenaemia prevalence data. 
Cryptococcal antigenaemia prevalence data have not been previously used to estimate 
incidence of cryptococcal meningitis.
Implications of all the available evidence
We estimated an average global cryptococcal antigen prevalence of 6% among HIV-
infected people with a CD4 cell count of less than 100 cells per µL. Annually, 278 000 
people have cryptococcal antigenaemia, with 73% of meningitis cases occurring in sub-
Saharan Africa. Cryptococcal meningitis causes 15% of AIDS-related deaths globally, 
yet remains neglected by numerous stakeholders. This study summarises the global scale 
of disease and highlights the need to implement cryptococcal prevention efforts.
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Figure 1. Cryptococcal antigenaemia prevalence studies of HIV-infected outpatient populations 
from 1989 to 2016
Error bars are 95% CI, the vertical dotted line represents the mean cryptococcal 
antigenaemia prevalence for all studies combined. Estimates of USA and UK were not 
included in final summary estimate of low-income and middle-income countries. Studies of 
populations in hospital were not included (appendix p 11). All references for the studies in 
this figure are in the appendix. MSF=Médecins Sans Frontieres. N=north. SE=southeast. 
SW=southwest.
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Figure 2. Annual incidence of cryptococcal infection by country
The annual number of people positive with cryptococcal antigenaemia estimated at 278 000 
(95% CI 195 500–340 600) globally in 2014. We estimated 223 100 annual incident cases of 
cryptococcal meningitis in 2014..
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Table 1
Model inputs and assumptions
Estimate (uncertainty interval)
Adults living with HIV19 31·8 million (30·1–33·7)
Adults with CD4 <350 cells per µL19 19·5 million (18·5–20·7)
CD4 <100 cells per µL of those CD4 <350 cells per µL
  Low-income and middle-income countries19–23 22·5% (19–26)
  High-income countries19–23 18·5% (16–21)
CD4 100–200 cells per µL of those CD4 <350 cells per µL
  Low-income and middle-income countries19–23 27·5% (24–31)
  High-income countries 31·5% (29–34)
Adults receiving ART19 11·3 million (10·4–12·7)
New initiation of ART19,24 2·3 million (1·8–2·8)
Retention in care (year 1)*25 Country-specific, regional estimate, weighted pooled average; total 
LTFU estimated at 1·1 million in 2014
Virological failure
  Virological failure (year 1)25,26 16% (12–20)
  Virological failure (year >2)*27–29 5·33% (4·0–6·6)
At risk for cryptococcal infection CD4 <100 cells per µL not on ART
CD4 <100 cells per µL on ART but LTFU or virological failure
CD4 100–200 cells per µL not on ART, LTFU, or virological failure
CD4 100–200 cells per µL no ART, LTFU, or virological 
failure10,30
25% of those with CD4 <100 cells per µL not on ART, or LTFU, or 
virological failure
CRAG prevalence
  For countries with multiple sources Weighted average of all sources and computed 95% CIs (figure 1)
  For countries without sources Regional weighted average (computed 95% CI)
CRAG-negative progression to CRAG-positive (without effective ART) CD4 <200 cells per µL
  Low-income and middle-income countries30 5·14 events per 100 person-years (2·6–9·0)
  High-income country30 2·57 events per 100 person-years (1·3–4·5)
CRAG positive who develop cryptococcal meningitis
  In care without pre-emptive treatment10–12,31,32 70% (56–84)
  Not in care10–12,31,32 95% (90–100)
Deaths from cryptococcal meningitis (1 year mortality)
  Low-income country33–39 70% (59–81)
  Middle-income country34,40–42 40% (34–46)
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Estimate (uncertainty interval)
  North America43,44 20% (12·5–27·5)
  Europe 30% (25–35)
  Death not in care (all regions)45 1·5 times higher
For more information see appendix. ART=antiretroviral therapy. LTFU=lost to follow-up. CRAG=cryptococcal antigenaemia.
*
Retention-in-care and virological failure in more than 2 years were assumed to be 33% of their year 1 value.
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Table 2
Burden of cryptococcal infection by region
Total cryptococcal
antigenaemia positive
(uncertainty interval)
Annual burden of
cryptococcal meningitis
(uncertainty interval)
Deaths from
cryptococcal meningitis
(uncertainty interval)
Sub-Saharan Africa 204 300 (148 400–237 800) 162 500 (113 600–193 900) 135 900 (93 900–163 900)
Asia and Pacific 52 300 (32 900–74 100) 43 200 (25 300–64 700) 39 700 (20 600–59 700)
Caribbean 1800 (1300–2200) 1400 (1000–1800) 700 (500–900)
Latin America 7000 (3600–11 100) 5300 (2600–8900) 2400 (1100–4400)
North America 3700 (3000–4600) 3000 (2300–3700) 700 (500–1000)
North Africa and Middle East 3600 (2600–5000) 3300 (2400–4500) 1900 (1300–2700)
Europe 5200 (4000–6500) 4400 (3400–5600) 1800 (1300–2400)
Global 278 000 (195 500–341 000) 223 100 (150 600–282 400) 181 100 (119 400–234 300)
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Table 3
Countries with the highest incidence of cryptococcal meningitis
Annual incidence
of cryptococcal
meningitis
Number at risk
(CD4
<100 cells per pL)
Cost of screening
all at risk (US$)*
HIV budget to
screen all
at risk (%)57
Nigeria 27 100 325 900 $1 303 437 0·23%
South Africa 21 400 382 400 $1 529 685 0·09%
Mozambique 18 600 184 300 $737 228 0·28%
India 18 300 209 900 $839 502 0·06%
Uganda 12 200 110 500 $441 933 0·08%
Ethiopia 9600 60 600 $242 561 0·06%
Kenya 9000 84 700 $329 138 0·08%
Tanzania 8400 117 200 $468 959 0·15%
DR Congo 8400 51 200 $204 889 0·24%
Zimbabwe 8100 92 400 $369 621 ··
Indonesia 6600 58 900 $235 564 0·27%
Zambia 5000 66 200 $264 611 0·10%
*
Based on presumed cost of cryptococcal antigenaemia lateral flow assay test of US$3 per test delivered price for resource-limited areas, with an 
additional $0·50 added for laboratory labour, and $0·50 for profit and overhead costs. Although not every person at risk will present to care, this 
gives an estimate of the magnitude of budgetary resources necessary to start screening. Further information about each estimate is available in the 
appendix.
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